Evaluating the Bioequivalence of Antibody–Drug Conjugates - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating the Bioequivalence of Antibody–Drug Conjugates
The authors discuss the analytical methods and related testing for bioequivalence studies of ADCs. This article is part of a special issue on analytical technology.


Pharmaceutical Technology
pp. s22-s27

References

1. T.T. Hansel, et al., Nature Rev. Drug Discov. 9 (4), 325–338 (2010).

2. D.R. Mould and K.R.D. Sweeney, Curr. Opin. in Drug Discov. Devel. 10, (1), 84–96 (2007).

3. Genentech, "Herceptin (trastuzumab) Intravenous Infusion, Full Prescribing Information" (South San Francisco, CA), http://www.gene.com/gene/products/information/oncology/herceptin/, accessed Oct. 10, 2011.

4. G.D. Lewis Phillips et al., Cancer Res. 68 (22), 9280–9290 (2008).

5. A. Beck, Discov. Med. 10 (53), 329–339 (2010).

6. I.E. Krop et al., J. Clinical Oncology 28 (16), 2698–2704 (2010).

7. H.A. Buris et al., et al. J. Clinical Oncology 29 (4), 398–405 (2011).

8. FDA, "FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from US Market," Press Release (Rockville, MD, June 21, 2010, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm, accessed Oct. 10, 2011.

9. EMA, Procedure No. EMEA/H/C/000705, EMEA/HMP/5130/2008 "Refusal Assessment Report for Mylotarg"(London, 2008).

10. P. Van Arnum, Pharm. Technol. 32 (6), 54–58 (2008).

11. A. Beck, T. Wurch, J.M. Reichert, Landes Biosci. 3 (2), 111–132 (2011).

12. A. Beck, P. Senter, and R. Chari, Landes Biosci. 3 (4) 331–337 (2011).

13. FDA, "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use" (Rockville, MD, Feb. 1997).

14. F. Ehmann, presentation at the GCC Workshop on Similar Biological Medicinal Products (Riyadh, Saudi Arabia, Apr. 19–20, 2011).

15. EMA, EMA/CHMP/BMWP/86289/2010, Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use (London, 2010).

16. Biophoenix, "Biosimilars, Biogenerics and Follow-on Biologics (Informa, UK 2007), http://www.scripintelligence.com/multimedia/archive/00000/BS1342_117a.pdf accessed Oct. 10, 2011.

17. A.G. Polson et al., Blood 110 (2), 616–623 (2007).

18. K. Anderson, presentation at the National Biotechnology Conference (San Francisco, 2011).

19. R.P. Lyon et al., presentation at the 101st Annual American Association for Cancer Research Meeting (Washington DC, 2010).

20. FDA, Guidance for Industry Safety Testing of Drug Metabolites (Rockville, MD, Feb. 2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here